JNJ · Johnson & Johnson

The thesis

Johnson & Johnson's newer drugs are growing fast enough to cover the loss of Stelara sales to biosimilars, and the company raised its 2026 outlook on 15 July 2026 on that strength. The shares have fallen anyway, to a $252.93 close on 5 October 2026, just above the $250 level that ends the case. The third-quarter report on 13 October 2026 settles it: it needs Innovative Medicine growth near the second quarter's pace and a 2026 sales outlook of at least $101.1 billion.

The operating record supports the case. Second-quarter sales rose 6.6% to $25.3 billion, according to the company's 15 July 2026 release. Innovative Medicine grew 6.8% operationally even though Stelara cut growth by about 7.6 percentage points. The company guides to $101.1 billion of 2026 sales and adjusted earnings per share (EPS) of $11.68 at the midpoint.

The price has weakened since the last update. The shares closed at $258.66 on 1 October 2026, $256.03 on 2 October 2026 and $252.93 on 5 October 2026, on days when growth sectors led the market (Benzinga sector reports, 2 October 2026 and 5 October 2026). The narrative is maturing: the drug recovery is well known, JPMorgan and BofA kept neutral ratings while raising targets on 29 September 2026, and the shares are down 3.5% over three months in adjusted daily closes. With the price this close to $250 a week before the report, the evidence leans toward the shares lagging the S&P 500 rather than leading it.

Bullish and bearish views on Johnson & Johnson

The bull case on Johnson & Johnson (JNJ), in brief: Outlook raised with sales above $100 billion. The bear case: Third-quarter EPS will look weak on charges.

Bull case

• Outlook raised with sales above $100 billion. On 15 July 2026 the company lifted adjusted EPS guidance by $0.13 to $11.68 and put 2026 sales at $101.1 billion. Barchart's 29 September 2026 survey shows full-year consensus EPS of $11.61, below the company's own midpoint.
• Launch drugs are outrunning the Stelara decline. Darzalex, Tremfya and Carvykti drove second-quarter growth per the company. BofA reported on 29 September 2026 that Tremfya prescriptions in inflammatory bowel disease were up 50% year over year and Caplyta prescriptions in depression up 60%.
• Trial results keep arriving. Caplyta met its Phase 3 goal in bipolar mania (21 September 2026), and Tecvayli plus Darzalex Faspro showed disease control and a survival benefit in the Phase 3 MajesTEC-3 trial (23 September 2026). On 2 October 2026 the company reported two-year Phase 3 ICONIC-TOTAL data in which 60% of scalp psoriasis patients and 89% of genital psoriasis patients on Icotyde reached the study's response measure.
• Carvykti durability supports the cell-therapy franchise. The company reported on 25 September 2026 that 50% of patients were progression-free five years after a single Carvykti infusion in a Phase 2 multiple myeloma trial.
• An orthopaedics sale could come soon. Bloomberg reported on 11 September 2026 that Apollo Global Management is in non-binding talks to buy DePuy Synthes for close to $20 billion. The unit had $9.3 billion of sales last year.
• The shares are deeply oversold. The 14-day relative strength index (RSI), a momentum gauge where readings under 30 mark heavy selling, stood at 22.4 on 5 October 2026, down from 28.2 on 2 October 2026.

Bear case

• Third-quarter EPS will look weak on charges. BofA's 29 September 2026 preview puts third-quarter EPS at $2.53, about 12% below consensus, because most of the $0.64 per share of 2026 acquired in-process research and development (IPR&D) charges land in the quarter. Published consensus figures disagree: Barchart lists $2.96, while Benzinga's 30 September 2026 preview cites $2.48 on revenue of $25.31 billion.
• MedTech is the slow half. MedTech grew 3.6% operationally to $8.926 billion in the second quarter, against 6.8% for Innovative Medicine, per the 15 July 2026 release.
• The price trend is down into the report. The shares closed lower on 1 October 2026, 2 October 2026 and 5 October 2026 and sit 9.2% below the $278.43 52-week high in adjusted daily closes.
• Valuation leaves less room. CNN Markets showed a price-to-earnings ratio of 29.68 and a market value of $609.51 billion on 5 October 2026.
• Talc litigation remains unresolved. A Louisiana jury found the company liable in a mesothelioma case in early September 2026, and the cases continue to be decided trial by trial.

Price setup

The last close was $252.93 on 5 October 2026, in an intraday range of $252.53 to $256.37 (CNN Markets). The 52-week high is $278.43, 9.2% above that close. Three-month performance is a 3.5% decline in adjusted daily closes.

The $250 round number is the nearest reference level below the price. A close under it would extend the slide that began from $258.66 on 1 October 2026. The RSI reading of 22.4 shows heavy recent selling; that condition has often preceded rebounds in large defensive stocks, though it does not fix a floor.

Crowding is low. The shares trade well below their high with momentum readings at oversold levels, and no recent company filings show share issuance. The main crowding factor is timing: the earnings report is six trading sessions away, with a known headline EPS drag from IPR&D charges.

Catalysts, next 30 days

• 13 October 2026 — Third-quarter 2026 results before the open, with an investor call at 8:30 a.m. ET. The report shows whether launches keep covering the Stelara decline and whether the $101.1 billion sales outlook holds or rises. Reported EPS will carry most of the year's IPR&D charges.
• ~31 October 2026, est. — A possible signed DePuy Synthes sale agreement, which Bloomberg said on 11 September 2026 could come within weeks. A deal near $20 billion would remove the slower orthopaedics unit from MedTech; collapsed talks would leave the mid-2027 separation route the company described in July.

What would change the view

The case breaks if the 13 October 2026 report shows Innovative Medicine operational growth falling well below the second quarter's 6.8%, or if the company lowers its $101.1 billion 2026 sales outlook. Either would mean launch drugs are no longer covering Stelara's erosion.

On price, a daily close below $250 would show the market rejecting the drug-recovery story before or after the report. A large talc verdict or settlement charge that lowers EPS guidance would also break it.

The read would strengthen if the company raises 2026 sales guidance above $101.1 billion and the shares recover toward the $278.43 52-week high, or if a DePuy Synthes sale near $20 billion is signed.

What it trades with

The shares trade with large-cap pharmaceutical and defensive health-care stocks and tend to lag when growth sectors lead, as on 2 October 2026 and 5 October 2026 per Benzinga's sector reports. Results from AbbVie and Merck in immunology and oncology shape sentiment toward the drug business. MedTech results and any DePuy Synthes deal link the shares to orthopaedic device makers such as Stryker and Zimmer Biomet.